Payment overview · 2025
General Payments
$1,264.66
62 reported records · 18 companies
Healthcare provider profile · identity verified
Jay Ross Connelley, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · MONTICELLO, AR · NPI 1649250689
Verified facts
What the public records show
CMS Open Payments records show Jay Ross Connelley, M.D. received $1,264.66 in general payments during 2025 across 62 reported records.
AstraZeneca Pharmaceuticals LP accounted for 20.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Kerendia, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 193 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 193 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 197 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $254.07 | 20.1% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $203.85 | 16.1% | 9 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $159.61 | 12.6% | 10 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $149.20 | 11.8% | 9 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $82.83 | 6.5% | 5 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $57.04 | 4.5% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $55.49 | 4.4% | 3 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $41.56 | 3.3% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $38.65 | 3.1% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $31.90 | 2.5% | 2 | 2025 |
| KVK-Tech, Inc. | Unresolved — no canonical attribution shown | $29.48 | 2.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $29.10 | 2.3% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $25.42 | 2.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.22 | 1.9% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $24.07 | 1.9% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $22.05 | 1.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.85 | 1.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.27 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,264.66 | 62 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $203.85 | 9 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $197.99 | 8 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $159.61 | 10 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $149.20 | 9 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $122.49 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $104.75 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $82.83 | 5 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $67.15 | 4 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $57.04 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $55.49 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $52.60 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $50.65 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $41.56 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $38.65 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $31.90 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $31.90 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $29.10 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $25.42 | 1 | 2025 |
Source payment records
|
|||||
| CARDIOMEMS Normalized: cardiomems |
Device | Abbott Laboratories | $24.22 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $24.07 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $22.05 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.85 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $17.27 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $15.68 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 197 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 75 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 193 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 60 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 70 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 80 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 87 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
55 | 23 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
75 | 20 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
60 | 27 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
193 | 48 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
87 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
193 | 48 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
70 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
80 | 23 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
197 | 41 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 758 | 209 |
| Amlodipine Besylate | Amlodipine Besylate | 691 | 171 |
| Gabapentin | Gabapentin | 510 | 134 |
| Omeprazole | Omeprazole | 487 | 157 |
| Levothyroxine Sodium | Levothyroxine Sodium | 481 | 110 |
| Ezetimibe | Ezetimibe | 477 | 123 |
| Lisinopril | Lisinopril | 443 | 128 |
| Losartan Potassium | Losartan Potassium | 429 | 122 |
| Diclofenac Sodium | Diclofenac Sodium | 424 | 174 |
| Furosemide | Furosemide | 417 | 141 |
| Pantoprazole Sodium | Pantoprazole Sodium | 389 | 105 |
| Metoprolol Tartrate | Metoprolol Tartrate | 376 | 106 |
| Potassium Chloride | Potassium Chloride | 376 | 113 |
| Prednisone | Prednisone | 373 | 235 |
| Hydrochlorothiazide | Hydrochlorothiazide | 367 | 110 |
| Metformin Hcl | Metformin Hcl | 340 | 90 |
| Fluticasone Propionate | Fluticasone Propionate | 311 | 155 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 300 | 124 |
| Tamsulosin Hcl | Tamsulosin Hcl | 257 | 76 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 253 | 144 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 245 | 67 |
| Donepezil Hcl | Donepezil Hcl | 219 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 219 | 57 |
| Citalopram Hbr | Citalopram Hydrobromide | 204 | 51 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 201 | 95 |
| Eliquis | Apixaban | 197 | 41 |
| Jardiance | Empagliflozin | 193 | 48 |
| Trazodone Hcl | Trazodone Hcl | 193 | 65 |
| Glimepiride | Glimepiride | 189 | 48 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 187 | 56 |
| Simvastatin | Simvastatin | 158 | 42 |
| Carvedilol | Carvedilol | 152 | 45 |
| Meloxicam | Meloxicam | 149 | 60 |
| Pravastatin Sodium | Pravastatin Sodium | 149 | 43 |
| Alendronate Sodium | Alendronate Sodium | 146 | 51 |
| Allopurinol | Allopurinol | 145 | 42 |
| Famotidine | Famotidine | 145 | 56 |
| Sucralfate | Sucralfate | 145 | 55 |
| Hydralazine Hcl | Hydralazine Hcl | 132 | 34 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 126 | 91 |
| Celecoxib | Celecoxib | 123 | 40 |
| Estradiol | Estradiol | 116 | 33 |
| Montelukast Sodium | Montelukast Sodium | 109 | 28 |
| Cefdinir | Cefdinir | 108 | 91 |
| Fluoxetine Hcl | Fluoxetine Hcl | 108 | 32 |
| Meclizine Hcl | Meclizine Hcl | 108 | 54 |
| Amitriptyline Hcl | Amitriptyline Hcl | 107 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 106 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 105 | 35 |
| Levofloxacin | Levofloxacin | 105 | 85 |
| Tizanidine Hcl | Tizanidine Hcl | 105 | 40 |
| Azithromycin | Azithromycin | 103 | 90 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 102 | 26 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 99 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 96 | 24 |
| Memantine Hcl | Memantine Hcl | 96 | 25 |
| Buspirone Hcl | Buspirone Hcl | 94 | 35 |
| Sertraline Hcl | Sertraline Hcl | 88 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 87 | 25 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 84 | 34 |
| Clonidine Hcl | Clonidine Hcl | 83 | 32 |
| Testosterone Cypionate | Testosterone Cypionate | 82 | 24 |
| Ozempic | Semaglutide | 80 | 23 |
| Topiramate | Topiramate | 80 | 21 |
| Finasteride | Finasteride | 78 | 18 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 76 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 76 | 24 |
| Farxiga | Dapagliflozin Propanediol | 75 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 73 | 20 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 72 | 52 |
| Mounjaro | Tirzepatide | 70 | 14 |
| Bupropion Xl | Bupropion Hcl | 68 | 20 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 68 | 42 |
| Glipizide | Glipizide | 67 | 17 |
| Spironolactone | Spironolactone | 67 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 65 | 18 |
| Baclofen | Baclofen | 63 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 60 | 50 |
| Kerendia | Finerenone | 60 | 27 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 59 | 22 |
| Xarelto | Rivaroxaban | 59 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 58 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 57 | 43 |
| Pregabalin | Pregabalin | 56 | 20 |
| Linzess | Linaclotide | 55 | 23 |
| Nitroglycerin | Nitroglycerin | 55 | 30 |
| Ventolin Hfa | Albuterol Sulfate | 54 | 28 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 52 | 45 |
| Oxybutynin Chloride | Oxybutynin Chloride | 52 | 20 |
| Clindamycin Hcl | Clindamycin Hcl | 51 | 46 |
| Mupirocin | Mupirocin | 51 | 29 |
| Fluconazole | Fluconazole | 50 | 38 |
| Mirtazapine | Mirtazapine | 50 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 50 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 48 | 31 |
| Promethazine Hcl | Promethazine Hcl | 48 | 23 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 47 | 12 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 45 | 21 |
| Latanoprost | Latanoprost | 45 | 14 |
| Tramadol Hcl | Tramadol Hcl | 45 | 19 |
| Dicyclomine Hcl | Dicyclomine Hcl | 44 | 18 |
| Mometasone Furoate | Mometasone Furoate | 44 | 28 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 44 | 16 |
| Methocarbamol | Methocarbamol | 43 | 13 |
| Metronidazole | Metronidazole | 41 | 36 |
| Doxycycline Hyclate | Doxycycline Hyclate | 38 | 34 |
| Verapamil Er | Verapamil Hcl | 38 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 37 | suppressed |
| Vascepa | Icosapent Ethyl | 37 | 14 |
| Dexamethasone | Dexamethasone | 35 | 33 |
| Valacyclovir | Valacyclovir Hcl | 35 | 15 |
| Clonazepam | Clonazepam | 34 | 20 |
| Januvia | Sitagliptin Phosphate | 34 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Nifedipine Er | Nifedipine | 33 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 33 | 11 |
| Atenolol | Atenolol | 32 | suppressed |
| Ibuprofen | Ibuprofen | 32 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 31 | suppressed |
| Gemfibrozil | Gemfibrozil | 31 | 11 |
| Terbinafine Hcl | Terbinafine Hcl | 31 | 25 |
| Trulicity | Dulaglutide | 31 | suppressed |
| Entresto | Sacubitril/Valsartan | 30 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 29 | 15 |
| Levetiracetam | Levetiracetam | 29 | suppressed |
| Methotrexate | Methotrexate Sodium | 29 | suppressed |
| Rybelsus | Semaglutide | 29 | suppressed |
| Tradjenta | Linagliptin | 29 | 11 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 28 | suppressed |
| Nystatin | Nystatin | 28 | 19 |
| Olanzapine | Olanzapine | 28 | suppressed |
| Ondansetron Odt | Ondansetron | 28 | 17 |
| Sumatriptan Succinate | Sumatriptan Succinate | 28 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 26 | 11 |
| Colchicine | Colchicine | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 24 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 23 | suppressed |
| Dantrolene Sodium | Dantrolene Sodium | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Folic Acid | Folic Acid | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Alogliptin | Alogliptin Benzoate | 20 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 20 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 20 | 13 |
| Divalproex Sodium | Divalproex Sodium | 20 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Alprazolam | Alprazolam | 19 | 11 |
| Carbamazepine | Carbamazepine | 19 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 19 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 19 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 19 | suppressed |
| Famciclovir | Famciclovir | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Trulance | Plecanatide | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 17 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 12 |
| Bumetanide | Bumetanide | 15 | suppressed |
| Carisoprodol | Carisoprodol | 15 | suppressed |
| Levemir | Insulin Detemir | 15 | suppressed |
| Premarin | Estrogens, Conjugated | 15 | suppressed |
| Azathioprine | Azathioprine | 14 | suppressed |
| Brilinta | Ticagrelor | 14 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Prolia | Denosumab | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 13 | suppressed |
| Humalog | Insulin Lispro | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 13 | 13 |
| Piroxicam | Piroxicam | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 13 | suppressed |
| Ssd | Silver Sulfadiazine | 13 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Butorphanol Tartrate | Butorphanol Tartrate | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | 11 |
| Diltiazem 12hr Er | Diltiazem Hcl | 11 | suppressed |
| Fetzima | Levomilnacipran Hcl | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 11 | 11 |
| Metolazone | Metolazone | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Timolol Maleate | Timolol Maleate | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,264.66 · 62 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAPLYTA, CARDIOMEMS, ELIQUIS, FARXIGA, JARDIANCE, Kerendia, LOKELMA, Leqembi, MOUNJARO, NURTEC ODT, Ohtuvayre, Ozempic, QULIPTA, Qelbree, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, WATCHMAN Access System, YUPELRI, ZAVZPRET | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error